论文部分内容阅读
三尖杉混合酯碱,即三尖杉酯碱(harringtonine)和高三尖杉酯碱(homoharringtonine)的混合物已进行过临床前药理研究,并于临床试治白血病中获得较满意的疗效,但此两个生物碱的组合比例在不同的制剂之间以及不同批号之间难以保持一致,给临床使用带来了很大不便,而且,两者的生物学特性究竟有何异同,亟待阐明。我们为提供毒理学资料给临床同志参考并从毒理学角度比较两药的特点,进行了两药的临床前毒理研究,现将主要结果总结报导如下,以供参考。
The mixture of harringtonine mixed ester base, namely harringtonine and homoharringtonine, has been subjected to preclinical pharmacological studies and has obtained satisfactory therapeutic effects in clinical trials of leukemia, but this The combination ratio of the two alkaloids is difficult to be consistent between different preparations and between different batch numbers, which brings great inconvenience to clinical use. Moreover, the difference between the biological characteristics of the two is urgently needed to be clarified. In order to provide toxicology data to clinical comrades and compare the characteristics of the two drugs from the perspective of toxicology, we conducted a preclinical toxicology study of the two drugs. The main findings are reported below for reference.